- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
J&J Gets CDSCO Panel Nod to study anticancer drug Cetrelimab
New Delhi: Pharmaceutical major Johnson and Johnson has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase III clinical trial (CT) of the anti-cancer drug Cetrelimab.
This came after the firm presented the proposal for Phase III clinical trial vide protocol no. 17000139BLC3002, amendment 1, dated 06-Dec-2022 before the committee.
Cetrelimab is under development for the treatment of metastatic or surgically unresectable urothelial cancer, chronic hepatitis B, muscle-invasive bladder cancer (MIBC), metastatic castration-resistant prostate cancer (second line and third line) advanced cancers such as colorectal cancer, non-small-cel
Cetrelimab works by trying to stimulate the immune system to attack prostate cancer by blocking a protein called PD-1. Giving apalutamide and cetrelimab together may cause the tumour to stop growing or grow at a slower rate in patients with prostate cancer.
Cetrelimab binds to PD-1 and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2).
At the recent SEC meeting for Oncology and Hematology held on the 30th of May 2023, the expert panel reviewed the proposal presented by Johnson and Johnson for Phase III clinical trial vide protocol no. 17000139BLC3002, amendment 1, dated 06-Dec-2022.
After detailed deliberation, the committee recommended the grant of permission for the conduct of the proposed Phase III clinical trial as presented by the firm.
Also Read:Monitor endometrioma size of participants: CDSCO panel tells Abbott India on Dydrogesterone
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.